{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:36:17Z","timestamp":1779924977757,"version":"3.53.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2000,1]]},"DOI":"10.1016\/s0959-8049(99)00264-6","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T21:34:59Z","timestamp":1027632899000},"page":"170-176","source":"Crossref","is-referenced-by-count":83,"title":["Assessment of HER2 status in breast cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"M","family":"Dowsett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J","family":"Gullick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Gusterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0959-8049(99)00264-6_BIB1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V","article-title":"Specificity within the EGF family\/erbB receptor family signalling network","volume":"20","author":"Riese","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.cb.10.110194.001343","article-title":"Receptor protein-tyrosine kinases and their signal transduction pathways","volume":"10","author":"van der Geer","year":"1994","journal-title":"Ann. Rev. Cell. Biol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-5793(97)00412-2","article-title":"The ErbB signaling network in embryogenesis and oncogenesis","volume":"410","author":"Alroy","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB4","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","article-title":"ErbB-2 is a common auxiliary subunit of NDF and EGF receptors","volume":"15","author":"Karunagaran","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB6","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","article-title":"Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"24","author":"Benz","year":"1992","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB8","first-page":"1859","article-title":"Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor","volume":"7","author":"Chazin","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB9","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","article-title":"Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells","volume":"84","author":"Hudziak","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0304-419X(94)90012-4","article-title":"The biology of erbB-2\/neu\/HER-2 and its role in cancer","volume":"1198","author":"Hynes","year":"1994","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu protooncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/bjc.1993.494","article-title":"Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth","volume":"68","author":"Harwerth","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0022-1759(90)90400-P","article-title":"ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids","volume":"132","author":"Sias","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/stem.160413","article-title":"The HER-2\/neu oncogene in breast cancer","volume":"16","author":"Ross","year":"1998","journal-title":"Stem Cells"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB17","first-page":"204","article-title":"Low concentrations of c-erbB-2 mRNA (real time RT-PCR) are associated with a poor prognosis in 404 unselected primary human breast cancers","volume":"40","author":"Pawlowski","year":"1999","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB18","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1177\/44.11.8918900","article-title":"Quantitative radioimmunohistochemical measurements of p185 (erbB-2) in frozen tissue sections","volume":"44","author":"Reeves","year":"1996","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB19","first-page":"3823","article-title":"Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer","volume":"56","author":"Robertson","year":"1996","journal-title":"Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/S0959-8049(99)00264-6_BIB20","first-page":"24","article-title":"Quantitation of c-erbB-2 in primary breast cancer","volume":"78","author":"Chong","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0959-8049(05)80117-0","article-title":"Overexpression of the c-erbB-2 oncogene","volume":"28A","author":"Barnes","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJM198811103191902","article-title":"Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in Stage II breast cancer","volume":"319","author":"van de Vijver","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB23","series-title":"American Society of Clinical Oncology educational book","first-page":"536","article-title":"Integration of new therapies into management of metastatic breast cancer: a focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development","author":"Piccart","year":"1999"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB24","first-page":"2435","article-title":"HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells","volume":"10","author":"Pietras","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0378-1119(94)00534-Y","article-title":"Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment","volume":"159","author":"Berns","year":"1995","journal-title":"Gene"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB26","first-page":"97A","article-title":"20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy","volume":"17","author":"Bianco","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.1995.13.5.1129","article-title":"Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer","volume":"13","author":"Leitzel","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB28","first-page":"1643","article-title":"Expression of epidermal growth factor receptor and c-erb B2 during the development of tamoxifen resistance in human breast cancer","volume":"3","author":"Newby","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB29","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0959-8049(05)80215-1","article-title":"Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity","volume":"29A","author":"Nicholson","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB30","first-page":"103a","article-title":"c-erbB2 is a marker of resistance to endocrine therapy in advanced breast cancer","volume":"17","author":"Plunkett","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/bjc.1992.22","article-title":"Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer","volume":"65","author":"Wright","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB32","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.1997.15.7.2518","article-title":"Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2\/c-neu protein","volume":"15","author":"Yamauchi","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bjc.1995.497","article-title":"Expression of ras p21, p53 and C-erbB-2 in advanced breast cancer and response to first line hormonal therapy","volume":"72","author":"Archer","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB34","first-page":"7","article-title":"HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer","volume":"4","author":"Elledge","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB35","first-page":"68a","article-title":"Lack of interaction of tamoxifen (T) use and ErbB-2\/HER-2\/neu (H) expression in CALGB 8541","volume":"18","author":"Muss","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1992.10.4.599","article-title":"HER-2\/neu in node-negative breast cancer","volume":"10","author":"Allred","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB37","first-page":"1441","article-title":"Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer","volume":"14","author":"Giai","year":"1994","journal-title":"Anticancer Res."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB38","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.1992.10.7.1049","article-title":"Prognostic importance of c-erbB-2 expression in breast cancer","volume":"10","author":"Gusterson","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB39","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/0959-8049(95)00344-4","article-title":"c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer","volume":"31A","author":"St\u00e5l","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB40","first-page":"69a","article-title":"Benefit of CMF treatment in lymph-node positive breast cancer overexpressing HER2","volume":"18","author":"M\u00e9nard","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<354::AID-IJC4>3.0.CO;2-6","article-title":"Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide\/methotrexate\/fluorouracil","volume":"84","author":"Miles","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB42","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","article-title":"c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer","volume":"330","author":"Muss","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose-intensity as determinants of outcome in the adjuvant treatment of breast cancer","volume":"90","author":"Budman","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB44","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jnci\/90.18.1346","article-title":"erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer","volume":"90","author":"Thor","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB45","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/90.18.1361","article-title":"erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer","volume":"90","author":"Paik","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB46","first-page":"97a","article-title":"Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone","volume":"17","author":"Ravdin","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.1998.16.2.470","article-title":"p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer","volume":"16","author":"Clahsen","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB48","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/bjc.1997.484","article-title":"Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer","volume":"76","author":"Niskanen","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.0.CO;2-Y","article-title":"No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer","volume":"79","author":"Rozan","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB50","doi-asserted-by":"crossref","unstructured":"Untch M, Thomssen C, Kahlert D, et al. Lack of c-erbB-2 overexpression predicts better response to dose intensification of anthracycline-based chemotherapy in high-risk breast cancer. Abstract no. 110 presented at the San Antonio Breast Cancer Conference, 12\u201315 Dec. 1998.","DOI":"10.1016\/S0959-8049(98)80125-1"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/00313029400169611","article-title":"Analysis of c-erbB2 expression using a panel of 6 commercially available antibodies","volume":"26","author":"Busmanis","year":"1994","journal-title":"Pathology"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB52","first-page":"2771","article-title":"Sensitivity of HER-2\/neu antibodies in archival tissue samples","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/path.1711730111","article-title":"Optimization of immunohistochemical detection of ERBB2 in human breast cancer","volume":"173","author":"Penault-Llorca","year":"1994","journal-title":"J. Pathol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB54","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/88.15.1054","article-title":"Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer","volume":"88","author":"Jacobs","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<273::AID-IJC13>3.0.CO;2-7","article-title":"c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples","volume":"84","author":"Farabegoli","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0959-8049(99)00264-6_BIB56","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.1999.17.7.2293b","article-title":"The HercepTest assay","volume":"17","author":"Espinoza","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB57","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.1999.17.7.1983","article-title":"Specificity of HercepTest in determining HER-2\/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system","volume":"17","author":"Jacobs","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB58","first-page":"1650","article-title":"Immunohistochemical assays for HER2 overexpression","volume":"17","author":"Maia","year":"1999","journal-title":"Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB59","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1999.17.1.434","article-title":"Increased HER2 with U.S. Food and Drug Administration-approved antibody","volume":"17","author":"Roche","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jcb.240390208","article-title":"Overexpression of the c-erbB-2 protein in human breast tumor cell lines","volume":"39","author":"Hynes","year":"1989","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB61","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/j.1460-2075.1987.tb04797.x","article-title":"Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms","volume":"6","author":"Kraus","year":"1987","journal-title":"EMBO J."},{"key":"10.1016\/S0959-8049(99)00264-6_BIB62","first-page":"63","article-title":"Detection and quantitation of HER-2\/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization","volume":"13","author":"Pauletti","year":"1996","journal-title":"Oncogene"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804999002646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804999002646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T18:07:18Z","timestamp":1580839638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804999002646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["S0959804999002646"],"URL":"https:\/\/doi.org\/10.1016\/s0959-8049(99)00264-6","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}